Novartis Warns of Pure Red Cell Aplasia Seen in Myfortic Patients

Novartis and the FDA are warning physicians and patients that cases of pure red cell aplasia have been associated with Myfortic, which is given to prevent transplant rejection. The patients involved were taking Myfortic (mycophenolic acid) in combination with other immunosuppressive agents, according to a MedWatch notice and “dear healthcare professional” letter issued last week. New postmarketing safety information has been added to the warnings and adverse reactions sections of the drug’s labeling, Novartis says in the letter sent to doctors.
Drug Industry Daily